ReviewChinese herbal medicines2022
Taxonomy of
Review in Chinese herbal medicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- An integrated approach: green extraction technique optimization, mechanistic study, and bioactivity profiling of four flavonoids fromRSC advances · 2026Article
- A comprehensive narrative review ofJournal of pharmaceutical analysis · 2026Review
- Discovery of anthraquinones as potent Notum inhibitors for treating osteoporosis by integrating biochemical, phytochemical, computational, and experimental assays.Journal of pharmaceutical analysis · 2026Article
- Diversity and epimedium biotransformation potential of cultivable endophytic fungi associated with Epimedium brevicornum Maxim in the Qinling Mountains, China.Microbial cell factories · 2025Article
- Exploring the molecular mechanism of Epimedium for the treatment of ankylosing spondylitis based on network pharmacology, molecular docking, and molecular dynamics simulations.Molecular diversity · 2025Article
- The therapeutic potential of icariin in the intervention of bone and joint diseases through multiple pathways: a narrative review.Frontiers in pharmacology · 2025Review
- Article
- Icariin as a Treatment Proposal in Mammalian Reproduction.Pharmaceuticals (Basel, Switzerland) · 2024Review
- A literature review onHeliyon · 2023Review
- Genetic and molecular analysis of the anthocyanin pigmentation pathway inFrontiers in plant science · 2023Article
- Parallel evolution, atavism, and extensive introgression explain the radiation ofFrontiers in plant science · 2023Article
- PhytoKeys · 2023Article
- DNA barcoding and comparative RNA-Seq analysis provide new insights into leaf formation using a novel resource of high-yieldingFrontiers in plant science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.